Kodiak Sciences (KOD) vs Scholar Rock (SRRK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Scholar Rock (SRRK) over the past year, gaining 540.1% versus a gain of 6.8%. Over five years, SRRK leads with a +54.7% price change compared with -18.7% for KOD. Kodiak Sciences is the larger company by market cap ($5.93 billion vs $5.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KOD | SRRK |
|---|---|---|
| Share price | $94.37 | $42.88 |
| Market cap | $5.93B | $5.22B |
| 1-day change | +3.61% | +1.61% |
| YTD return | +225.75% | -4.20% |
| 1-year return | +540.06% | +6.84% |
| 5-year return | -18.66% | +54.75% |
| EPS (TTM) | $-4.19 | $-3.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-229.97M | $-377.94M |
| 52-week high | $104.00 | $61.76 |
| 52-week low | $10.94 | $27.07 |
| Distance from 52-week high | -9.26% | -30.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +23.64% | +64.27% |
| Average volume | 1.56M | 1.49M |
| Shares outstanding | 62.85M | 121.79M |
| Employees | 141 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed SRRK by 533.2 percentage points over the past year.
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Scholar Rock
SRRK stock →Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees
KOD vs SRRK FAQ
Which is bigger, Kodiak Sciences or Scholar Rock?
Kodiak Sciences (KOD) is larger, with a market capitalization of $5.93B compared with $5.22B for Scholar Rock (SRRK).
Which stock has performed better over the past year, KOD or SRRK?
KOD returned +540.06% over the past 12 months, compared with +6.84% for SRRK (price return, excluding dividends). Past performance does not predict future results.
Are Kodiak Sciences and Scholar Rock in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.